company background image
MITRA logo

Mithra Pharmaceuticals ENXTBR:MITRA Stock Report

Last Price

€0.53

Market Cap

€36.4m

7D

-2.4%

1Y

-78.1%

Updated

03 Mar, 2024

Data

Company Financials +

Mithra Pharmaceuticals SA

ENXTBR:MITRA Stock Report

Market Cap: €36.4m

MITRA Stock Overview

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally.

MITRA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Mithra Pharmaceuticals SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mithra Pharmaceuticals
Historical stock prices
Current Share Price€0.53
52 Week High€3.93
52 Week Low€0.50
Beta0.54
1 Month Change-50.93%
3 Month Change-55.27%
1 Year Change-78.08%
3 Year Change-97.37%
5 Year Change-97.96%
Change since IPO-95.60%

Recent News & Updates

Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Feb 07
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

Nov 09
Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

Recent updates

Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Feb 07
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

Nov 09
Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Oct 05
These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

May 23
Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Aug 11
Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mar 13
Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Dec 22
Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 24
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

Jun 07
Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

May 10
When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

Mar 18
Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Jan 21
Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 29
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Shareholder Returns

MITRABE PharmaceuticalsBE Market
7D-2.4%-0.5%-1.1%
1Y-78.1%12.7%-5.1%

Return vs Industry: MITRA underperformed the Belgian Pharmaceuticals industry which returned 12.7% over the past year.

Return vs Market: MITRA underperformed the Belgian Market which returned -5.1% over the past year.

Price Volatility

Is MITRA's price volatile compared to industry and market?
MITRA volatility
MITRA Average Weekly Movement13.9%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement3.5%
10% most volatile stocks in BE Market6.8%
10% least volatile stocks in BE Market2.3%

Stable Share Price: MITRA's share price has been volatile over the past 3 months.

Volatility Over Time: MITRA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
1999270David Solomonhttps://www.mithra.com

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.

Mithra Pharmaceuticals SA Fundamentals Summary

How do Mithra Pharmaceuticals's earnings and revenue compare to its market cap?
MITRA fundamental statistics
Market cap€36.35m
Earnings (TTM)-€78.84m
Revenue (TTM)€62.68m

0.6x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MITRA income statement (TTM)
Revenue€62.68m
Cost of Revenue€20.97m
Gross Profit€41.71m
Other Expenses€120.55m
Earnings-€78.84m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 08, 2024

Earnings per share (EPS)-1.14
Gross Margin66.54%
Net Profit Margin-125.79%
Debt/Equity Ratio-3,048.5%

How did MITRA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.